On Monday, BofA Securities maintained a positive stance on Bruker (NASDAQ:BRKR) Corporation (NASDAQ:BRKR), reiterating its Buy rating and a price target of $80.00. The endorsement comes as Bruker revealed preliminary results for the fourth quarter of 2024 and provided an initial outlook for the fiscal year 2025 ahead of a conference presentation scheduled for later in the day.
According to InvestingPro data, the company, currently valued at $9.4 billion, trades at a relatively high P/E multiple of 30x, suggesting investors are pricing in strong growth expectations.
Bruker anticipates fourth-quarter total revenue to land between $970 million and $980 million, surpassing both BofA Securities' estimate (BofAe) and the consensus on the Street, which stood at $968 million and $955 million, respectively. The company also indicated that bookings for Bruker Scientific Instruments (BSI) in the fourth quarter were robust.
This performance builds on the company's strong revenue growth of 15% over the last twelve months, as reported by InvestingPro, which offers comprehensive financial analysis through its Pro Research Reports covering 1,400+ top US stocks.
For the fiscal year 2025, Bruker has set a preliminary guide for constant currency (CC) exchange rate growth in the upper mid-single digits (MSD), assuming a low-single-digit (LSD) market growth. This forecast is slightly higher than the estimates by BofA Securities and the consensus, which were 7.9% and 7.2%, respectively.
The firm's analysts are keen to get further details on the composition of the projected upper MSD growth rate, particularly how much of it can be attributed to organic growth versus mergers and acquisitions, such as the recent NanoString deal. Clarity on these details is anticipated during the management's presentation at the conference, where they will discuss the drivers behind the results and guidance.
BofA Securities' endorsement of Bruker's stock is based on several factors. The firm notes that Bruker boasts one of the best new product portfolios in the industry, has been executing well despite a challenging environment, and possesses the capability to implement cost reductions in its recently acquired entities to bolster earnings per share (EPS).
InvestingPro analysis supports this positive outlook, showing a "GOOD" overall financial health score and strong cash flows sufficient to cover interest payments. InvestingPro subscribers have access to over 10 additional key insights about Bruker's financial position and growth prospects.
In other recent news, Bruker Corporation has announced preliminary fourth-quarter 2024 revenue, expected to be between $970 million to $980 million, surpassing the consensus estimate of $962 million. This announcement follows a robust 15% revenue growth over the last year, as noted by Citi analysts, who have maintained a Buy rating on Bruker with a price target of $75.00. In addition to this, Bruker anticipates constant currency revenue growth in the upper-mid single digits for 2025.
In legal developments, Bruker faces a patent infringement case, with the U.S. District Court for the District of Delaware upholding a jury's decision to award damages to 10x Genomics (NASDAQ:TXG). The court confirmed damages of approximately $31.6 million against Bruker's NanoString business unit. Despite this setback, Bruker plans to appeal the case.
Bruker Corporation has also been evaluated by several financial firms. Guggenheim initiated coverage, assigning a Buy rating and setting a price target of $72.00, highlighting Bruker's undervalued position. UBS assumed coverage with a Neutral rating and a price target of $66.00, while Goldman Sachs upgraded Bruker's stock from Sell to Neutral, maintaining a price target of $60.00.
In terms of product innovation, Bruker launched the Dimension Nexus atomic force microscope, a versatile and high-performance addition to its Dimension AFM product line.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.